Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Closed 05-13 16:00:00 EDT

53.92

+0.47

+0.88%

High54.16	Low53.46	Vol597.54M
Open53.46	D1 Closing53.45	Amplitude1.31%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O10.08B	T/O Rate--	Tradable Shares0.00
P/B5.508028	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":53.91595,"timestamp":1715630399999,"preClose":53.44807,"halted":0,"volume":597535907,"delay":0,"changeRate":0.008754,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":0.46788,"latestTime":"05-13 16:00:00 EDT","open":53.457325,"high":54.160053,"low":53.457325,"amount":10079298191.584387,"amplitude":0.013148,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1715644800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.508028,"peRate":-43.055427,"turnoverRate":0.01904,"increases":306,"decrements":266,"flats":21,"marketCap":1412590177775.875,"floatMarketCap":1267506548111.3672},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2435044343","title":"BRIEF-FDA Says On May 9, Cue Health Inc Got Warning Letter From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2435044343","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435044343?lang=en_us&edition=fundamental","pubTime":"2024-05-14 03:48","pubTimestamp":1715629704,"startTime":"0","endTime":"0","summary":"May 13  - FDA:   * FDA: ON MAY 9, CUE HEALTH INC GOT WARNING LETTER FROM FDA   * FDA-DURING INSPECTION,INVESTIGATOR DETERMINED CUE HEALTH MARKETS, DISTRIBUTES CUE HEALTH COVID-19 TEST & CUE HEALTH COVID-19 TEST FOR HOME & OTC USE   * FDA: INSPECTION REVEALED CUE HEALTH INC IS NOT COMPLYING WITH SOME CONDITIONS OF AUTHORIZATION IN LETTERS OF AUTHORIZATION FOR EUA200248 & EUA210180Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435304307","title":"William Blair Remains a Hold on Legend Biotech (LEGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435304307","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435304307?lang=en_us&edition=fundamental","pubTime":"2024-05-14 03:35","pubTimestamp":1715628919,"startTime":"0","endTime":"0","summary":"In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech (LEGN – Research Report). The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-hold-on-legend-biotech-legn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-hold-on-legend-biotech-legn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435530146","title":"CareDx cut to market perform by Raymond James over valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2435530146","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435530146?lang=en_us&edition=fundamental","pubTime":"2024-05-14 03:07","pubTimestamp":1715627236,"startTime":"0","endTime":"0","summary":"Raymond James has downgraded its rating on CareDx  to market perform, citing last week’s run up in the stock following the company’s better-than-expected Q1 report and the Centers for Medicare and Medicaid Services’ proposed Increased Organ Transplants Access, or IOTA, plan. The investment firm said it was lowering its rating “somewhat begrudgingly” as it believes the quarterly report showed a “healthy sequential trajectory that should prove durable” and “IOTA, if implemented, clearly adds to the story.”  However, Raymond James also believes that “some upside” is priced in, “keeping us from calling for more room for the stock to run even if we like the fundamentals.” The investment firm raised it price target for the stock to $15 from $13.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1015828796/image_1015828796.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1015828796/image_1015828796.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105396-caredx-cut-to-market-perform-by-raymond-james-over-valuation","is_publish_highlight":false,"gpt_icon":0},{"id":"2435912301","title":"Incyte Buyback Seen Luring Value Investors -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2435912301","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435912301?lang=en_us&edition=fundamental","pubTime":"2024-05-14 03:06","pubTimestamp":1715627160,"startTime":"0","endTime":"0","summary":"1506 ET - Incyte's massive stock buyback is treating investors' headaches about an upcoming patent cliff. Cantor Fitzgerald analyst Eric Schmidt said in a research note last month that the cancer drug Jakafi has a 2029 patent expiration, which is seen as a major risk for investors. The patent lapsing would strip Incyte of billions of dollars in potential revenue. He called for a major stock buyback, arguing it would demonstrate a drive to return value to shareholders and would lure in value investors. Schmidt got his wish on Monday, when Incyte announced a $2 billion stock repurchase program. Shares rise 8.1% to $57.34. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435772309","title":"GameStop Stock Is Proof the Fed Must Raise Rates Again","url":"https://stock-news.laohu8.com/highlight/detail?id=2435772309","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2435772309?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:51","pubTimestamp":1715626301,"startTime":"0","endTime":"0","summary":"GameStop stock is soaring seemingly because Roaring Kitty returned to social media. The real reason is too much market froth.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/gamestop-stock-is-proof-the-fed-must-raise-rates-again/","is_publish_highlight":false,"gpt_icon":0},{"id":"2435309135","title":"Praxis Precision Medicines Shares Drop 5% After 1Q Results Miss Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2435309135","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435309135?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:42","pubTimestamp":1715625720,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines shares dropped after the company reported a loss for the first quarter that was wider than analyst expectations. Shares were down 5.7% to $46.01. The stock has more than doubled in value this year.The company reported a net loss of $39.6 million, or $2.84 a share, versus a loss of $37.6 million, or $10.58 a share, a year ago.Analysts polled by FactSet were expecting a loss of $2.08 per share.Collaboration revenue was $431,000, while analysts polled by FactSet were expecting $1.9 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435301941","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2435301941","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2435301941?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:41","pubTimestamp":1715625712,"startTime":"0","endTime":"0","summary":"CareCloud  on Monday released details of an \"unsolicited, non-binding indication of interest\" on March 4 to acquire the company for $5 per share.The offer included a $25 redemption price per share for the company's 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock.Shares of CareCloud surged 84.5% as intraday trading volume catapulted to over 85.6 million from a daily average of about 55,000.GameStop  shares soared nearly 78% after \"Roaring Kitty\" -- the social media persona behind the 2021 rally in the video game retailer's stock -- resurfaced on X after a seemingly three-year hiatus.More than 147.5 million shares traded intraday compared with a daily average of about 7.1 million.AC Immune  and Takeda Pharmaceutical  unveiled on Monday an exclusive, worldwide option and license agreement for AC Immune's immunotherapies, including its Alzheimer's disease treatment candidate.Shares of AC Immune soared 32% as intraday trading volume shot to more than 27.6 million from a daily","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-midday-gainers-184152520.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435996309","title":"Twist Bioscience launches MGF product, stock climbs 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435996309","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435996309?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:35","pubTimestamp":1715625346,"startTime":"0","endTime":"0","summary":"Twist Bioscience  stock was up 10% in afternoon trading Monday after the company announced it has launched its Twist Multiplexed Gene Fragments, or MGFs. Twist said the MGFs are pools of directly synthesized double-stranded DNA up to 500 base pairs in length with no limit on sequence number to allow for high throughput screening applications.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1466682913/image_1466682913.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1466682913/image_1466682913.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105389-twist-bioscience-launches-mgf-product-stock-climbs","is_publish_highlight":false,"gpt_icon":0},{"id":"2435830642","title":"Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Annexon Biosciences (ANNX) and Cytokinetics (CYTK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435830642","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435830642?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:10","pubTimestamp":1715623845,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zimmer Biomet Holdings (ZBH – Research Report), An...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zimmer-biomet-holdings-zbh-annexon-biosciences-annx-and-cytokinetics-cytk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zimmer-biomet-holdings-zbh-annexon-biosciences-annx-and-cytokinetics-cytk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435306164","title":"PLL, TSE and FF are among materials movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2435306164","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435306164?lang=en_us&edition=fundamental","pubTime":"2024-05-14 02:04","pubTimestamp":1715623496,"startTime":"0","endTime":"0","summary":"Gainers: Critical Metals (CRML) +12%.Osisko Development (ODV) +12%.Origin Agritech (SEED) +11%.Piedmont Lithium (PLL) +10%.Global Gas (HGAS) +10%.Losers: Yield10 Bioscience (YTEN) -10%.Trinseo (TSE) -10%.Futurefuel (FF) -8%.Loma Negra Compania Industrial Argentina (LOMA) -6%.Northern Technologies International (NTIC) -5%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105365-pll-tse-and-ff-are-among-materials-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2435306311","title":"Novavax Shares Pop Another 50% Following Sanofi Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2435306311","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435306311?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:59","pubTimestamp":1715623140,"startTime":"0","endTime":"0","summary":"Shares of Novavax continued their ascent on Monday, adding to gains from last week after the company announced a licensing deal with Sanofi.The stock was up 50% to $13.31 in afternoon trading, reaching its highest intraday level since December 2022. Shares roughly doubled on Friday following the news, and are now up more than threefold in the last three months.Novavax said Friday morning that it had agreed to a licensing deal with Sanofi to commercialize its Covid-19 vaccine worldwide. The company said it would receive up to $1.4 billion under the deal, inclusive of milestone payments.Sanofi will have the sole license to use the Covid-19 vaccine in combination with its flu vaccine.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435051313","title":"Cytokinetics Data Drop Flashes Potential Safety Signal -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2435051313","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435051313?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:40","pubTimestamp":1715622000,"startTime":"0","endTime":"0","summary":"1340 ET - Cytokinetics's latest data on its promising heart drug may contain a warning sign on safety. According to Mizuho analyst Salim Syed, more extensive data from Cytokinetics's aficamten, a potential treatment for hypertrophic cardiomyopathy, shows 12 total cases where left ventricular ejection fraction, a measure of heart function, reached a problematic level. Eleven of those 12 cases were in trial subjects treated with aficamten, rather than the placebo. That might be a issue in investors' eyes, Syed says, since Cytokinetics is looking to compete with Bristol Myers Squibb's Camzyos -- already approved for HCM -- by being a safer alternative. Cytokinetics shares drop 6.1%. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435305948","title":"GameStop shorts lose $1B on paper during Monday's meme stock rally - S3 Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2435305948","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435305948?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:35","pubTimestamp":1715621709,"startTime":"0","endTime":"0","summary":"Short-sellers in GameStop (NYSE:GME) logged more than $1B in paper losses Monday stemming from the sudden rally in the shares, according to S3 Partners. GameStop (GME) rocketed more than 100% and surp","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357928341/image_1357928341.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357928341/image_1357928341.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105335-gamestop-shorts-lose-1b-on-paper-during-mondays-meme-stock-rally-s3-partners","is_publish_highlight":false,"gpt_icon":0},{"id":"2435090883","title":"Update: AstraZeneca Sued by Trial Participant For Alleged Injury During COVID-19 Vaccine Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2435090883","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2435090883?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:35","pubTimestamp":1715621706,"startTime":"0","endTime":"0","summary":"AstraZeneca's  was sued Monday by a trial participant in its COVID-19 vaccine study for failing to cover her medical costs following an injury.Brianne Dressen alleged in her claim that the drugmaker's vaccine caused what doctors later diagnosed as post-vaccine neuropathy and that the company did not honor a contractual commitment to pay for medical treatment if a trial participant suffered a so-called research injury, as she had.According to the lawsuit, Dressen in 2020 participated in AstraZeneca's clinical trial in Salt Lake County, Utah, and began experiencing \"progressively worrying symptoms\" within hours of getting a shot of the company's experimental COVID-19 vaccine.The symptoms included paresthesia, a term used to describe tingling and prickling under the skin. Dressen was diagnosed months later by neurologists at the National Institute of Health with post-vaccine neuropathy and remains disabled, the lawsuit said.AstraZeneca offered a \"paltry sum\" of $1,243.30 to Dressen after ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-sued-trial-participant-alleged-173506193.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435330534","title":"FFIE, OGEN and CCLD among mid-day movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2435330534","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435330534?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:30","pubTimestamp":1715621451,"startTime":"0","endTime":"0","summary":"Gainers: CareCloud  +77%. Gamestop Corporation  +64%. AMC Entertainment Holdings  +48%. Novavax  +50%. Tupperware Brands Corporation  +43%. AC Immune  +39%. Faraday Future Intelligent Electric  +34%. VinFast Auto Ltd.  +31%. Macrogenics  +31%.  Koss Corp.  +29%.  Losers: TransCode Therapeutics  -43%. Seritage Growth Properties  -31%. Amprius Technologies  -28%. Antelope Enterprise Holdings Ltd  -25%. 1847 Holdings LLC  -23%. Telesis Bio  -18%. Benitec Biopharma  -17%. Oragenics  -17%. Strong Global Entertainment  -16%. Fortrea Holdings  -16%.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215119911/image_1215119911.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105333-ffie-ogen-and-ccld-among-mid-day-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2435305345","title":"Corbus Pharmaceuticals a new outperform at RBC on cancer, obesity assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2435305345","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435305345?lang=en_us&edition=fundamental","pubTime":"2024-05-14 01:24","pubTimestamp":1715621057,"startTime":"0","endTime":"0","summary":"RBC Capital Markets has initiated Corbus Pharmaceuticals (NASDAQ:CRBP) at outperform citing the potential of an antibody-drug conjugate for solid tumors and a potential alternative or combination cand","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173024040/image_173024040.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173024040/image_173024040.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105325-corbus-pharmaceutical-new-outperform-rbc-cancer-obesity-assets","is_publish_highlight":false,"gpt_icon":0},{"id":"2435430327","title":"US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2435430327","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2435430327?lang=en_us&edition=fundamental","pubTime":"2024-05-14 00:51","pubTimestamp":1715619071,"startTime":"0","endTime":"0","summary":"US equity indexes traded mixed after midday on Monday as expectations for inflation one year ahead increased, adding to concern near-term price pressures are growing in the economy.The S&P 500 was up less than 0.1% at 5,224.2, and the Nasdaq Composite rose 0.3% to 16,394.7. The Dow Jones Industrial Average slipped less than 0.1% to 39,498.3. Technology and materials were the sole decliners intraday. Communication services led the decliners.In economic news, consumer expectations for one-year US inflation growth increased to 3.3% in April after remaining at a 3% pace for four consecutive months, according to a New York Federal Reserve Bank survey Monday. The median expectations slowed to a 2.8% gain from a 2.9% increase for the upcoming three years but rose to a 2.8% jump from a 2.6% advance for the five years ahead.Following three hotter-than-expected reports in January, February, and March, the April consumer price index data is due Wednesday. The producer price index for the month is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-equity-indexes-trade-mixed-165111597.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435308080","title":"Merus gets FDA breakthrough therapy status for petosemtamab","url":"https://stock-news.laohu8.com/highlight/detail?id=2435308080","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435308080?lang=en_us&edition=fundamental","pubTime":"2024-05-14 00:47","pubTimestamp":1715618841,"startTime":"0","endTime":"0","summary":"Merus  has received breakthrough therapy designation for its drug candidate petosemtamab in the treatment of certain patients with head and neck cancer. Petosemtamab received the designation for patients with recurrent or metastatic head and neck squamous cell carcinoma, or HNSCC, whose disease has progressed following treatment with platinum-based chemotherapy and a PD-1 or PD-L1 antibody. The product was already given fast track designation. Merus expects to release updated data from a Phase 1/2 study of the product as a monotherapy in the second half of 2024. The company hopes to initiate a Phase 3 study of petosemtamab in the treatment of previously treated HNSCC patients in mid-2024.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162781707/image_1162781707.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162781707/image_1162781707.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105323-merus-gets-fda-breakthrough-therapy-status-for-petosemtamab","is_publish_highlight":false,"gpt_icon":0},{"id":"2435308932","title":"Arrowhead Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2435308932","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435308932?lang=en_us&edition=fundamental","pubTime":"2024-05-14 00:47","pubTimestamp":1715618820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARWR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2024 12:47 ET (16:47 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435309185","title":"Top Analyst Reports for Boston Scientific, Arista Networks & Palo Alto Networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2435309185","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435309185?lang=en_us&edition=fundamental","pubTime":"2024-05-14 00:44","pubTimestamp":1715618640,"startTime":"0","endTime":"0","summary":"Monday, May 13, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-boston-scientific-164400640.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}